Cite
HARVARD Citation
Borchmann, P. et al. (n.d.). Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet oncology. 18 (4), pp. 454-463. [Online].